Working… Menu

A Study of the Safety and Efficacy of Infliximab (Remicade) in Subjects With Fistulizing Crohn's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00207766
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : April 27, 2010
Information provided by:
Centocor, Inc.

Brief Summary:
A study of infliximab in patients with Fistulizing Crohn's Disease

Condition or disease Intervention/treatment Phase
Crohn Disease Drug: infliximab or placebo Phase 3

Detailed Description:

This is a medical research study for patients with Crohn's disease who have one or more draining enterocutaneous fistula (fistula from the bowel to the skin). Fistulas are a common complication of Crohn's disease. Fistulas rarely close spontaneously but they may get better with treatment of the underlying Crohn's disease. This study will investigate the safety and efficacy of maintenance dosing of an anti-TNF (anti-tumor necrosis factor) antibody (a protein), called infliximab, compared to a placebo (inactive substance) in providing sustained reductions in the number of draining fistulas.

Subjects will receive infliximab at weeks 0, 2 and 6 followed by infusions of infliximab 5 mg/kg or placebo at weeks 14 and every 8 weeks until week 46. Patients who lose response are eligible for increasing treatment by 5 mg/kg of infliximab.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 306 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: ACCENT II - A Randomized, Double-blind, Placebo-controlled Trial of Anti-TNF Chimeric Monoclonal Antibody (Infliximab, Remicade) in the Long Term Treatment of Patients With Fistulizing CROHN'S Disease
Study Start Date : June 2000
Actual Study Completion Date : August 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Crohn's Disease
Drug Information available for: Infliximab

Primary Outcome Measures :
  1. Reduction in the number of draining fistulas

Secondary Outcome Measures :
  1. Complete fistula response (no draining fistula).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Single or multiple draining fistulas
  • Crohn's disease of at least 3 months' duration,

Exclusion Criteria:

  • Crohn's disease complications for which surgery might be indicated
  • Positive stool culture

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00207766

Sponsors and Collaborators
Centocor, Inc.
Layout table for investigator information
Study Director: Centocor, Inc. Clinical Trial Centocor, Inc.
Publications of Results:
Layout table for additonal information Identifier: NCT00207766    
Other Study ID Numbers: CR005413
First Posted: September 21, 2005    Key Record Dates
Last Update Posted: April 27, 2010
Last Verified: January 2009
Keywords provided by Centocor, Inc.:
Crohn's Disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Crohn Disease
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Dermatologic Agents
Gastrointestinal Agents
Antirheumatic Agents